A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study-Reference-Cited by-同舟云学术

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study

Published:2011-07 Issue:1 Volume:122 Page:111-115
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Coleman Robert L.,Brady William E.,McMeekin D. Scott,Rose Peter G.,Soper John T.,Lentz Samuel S.,Hoffman James S.,Shahin Mark S.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference38 articles.

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. [comment];McGuire;New Eng J Med,1996

2. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group;Miller;J Clin Oncol,2009

3. Phase II trial of weekly paclitaxel (80mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study;Markman;Gynecol Oncol,2006

4. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study;Rose;Gynecol Oncol,2003

5. Protein nanoparticles as drug carriers in clinical medicine;Hawkins;Adv Drug Deliv Rev,2008

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies;Clinical Cancer Research;2024-03-26

2. Microtubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy;Advances in Experimental Medicine and Biology;2024

3. Systemische Therapie der epithelialen serösen Ovarialkarzinome;Deutsche Zeitschrift für Onkologie;2023-12

4. Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study;Journal of Clinical Oncology;2023-10-20

5. Lymphatic vasculature in ovarian cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-09